脉冲降低剂量率放疗对大体积复发脑膜瘤的大剂量再照射
回顾性分析8例既往接受过常规放疗的复发颅内脑膜瘤患者,采用脉冲降低剂量率放疗(PRDR)再照射,中位剂量54 Gy/27次,中位体积261.6 cm³。中位随访23.3个月,2例(25%)野内失败,6个月无进展生存率100%,无≥2级急慢性毒性。作者认为PRDR再照射耐受良好且似有效,正在筹备II期前瞻性试验。
要点
- 8例复发脑膜瘤再照射采用PRDR,中位剂量54 Gy/27次,中位体积261.6 cm³。
- 中位随访23.3个月,2例(25%)野内失败,6个月PFS为100%。
- 无患者出现≥2级急性或晚期毒性,除1例外余均存活。
核心结论
- PRDR再照射对既往接受过放疗的小队列复发脑膜瘤患者耐受良好且似有效。
- 作者提及正在筹备II期前瞻性试验以评估该疗法。
研究设计与样本
- 回顾性识别2013年4月至2017年8月在同一机构接受PRDR治疗的8例复发颅内脑膜瘤患者。
- 所有患者治疗前均有影像学和/或病理学进展证据,且既往已完成常规放疗。
- 急性与晚期毒性按CTCAE 4.0分级。
主要发现
- 8例中6例复发时组织学确诊为非典型脑膜瘤。
- 所有患者接受IMRT再治疗,表观剂量率为0.0667 Gy/min。
- 两次放疗课程中位间隔7.7年。
- PRDR中位剂量54 Gy分27次,中位体积261.6 cm³。
- 中位随访23.3个月,2例(25%)出现野内失败,6个月无进展生存率为100%,除1例(87.5%)外其余患者末次随访时仍存活。
关键数值与推荐
- 无患者发生≥2级急性或晚期毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为回顾性研究,样本量小(8例)。
- 作者提及正在筹备II期前瞻性试验以评估该疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Meningiomas comprise up to 30% of primary brain tumors. The majority of meningioma patients enjoy high rates of control after conventional therapies. However, patients with recurrent disease previously treated with radiotherapy have few options for salvage treatment, and systemic interventions have proven largely ineffective. The aim of this study was to determine whether pulsed reduced dose rate radiotherapy (PRDR) was well tolerated in a small cohort of patients with recurrent meningioma. METHODS: We retrospectively identified eight patients with recurrent intracranial meningioma treated with PRDR from April 2013 to August of 2017 at a single institution. All patients had radiographic and/or pathologic evidence of progression prior to treatment and had previously completed conventional radiotherapy. Acute and late toxicities were graded based on CTCAE 4.0. RESULTS: Of eight patients, six had histologically confirmed atypical meningiomas upon recurrence. All patients were re-treated with IMRT at an apparent dose rate of 0.0667 Gy/min. Median time between radiation courses was 7.7 years. Median PRDR dose was 54 Gy in 27 fractions to a median volume of 261.6 cm3. Two patients (25%) had in field failure with a median follow up of 23.3 months. PFS at 6 months was 100%. All but one (87.5%) patient was still alive at last follow up. No patient experienced grade ≥ 2 acute or late toxicities. CONCLUSIONS: PRDR re-irradiation was well tolerated and appeared effective for a small cohort of patients with recurrent meningioma previously treated with radiotherapy. A phase II trial to assess this prospectively is in development.
引用
- Witt JS, Musunuru HB, Bayliss RA, et al. Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy. J Neurooncol. 2018. PMID: 30392090. doi:10.1007/s11060-018-03011-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。